TELA - TELA Bio, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
14.37
+0.48 (+3.46%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close13.89
Open13.94
Bid0.00 x 1100
Ask0.00 x 800
Day's Range13.94 - 14.37
52 Week Range5.25 - 18.88
Volume5,684
Avg. Volume45,295
Market Cap163.927M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-6.48
Earnings DateMay 12, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      TELA Bio Announces First Quarter 2020 Financial Results

      MALVERN, Pa., May 12, 2020 -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new.

    • GlobeNewswire

      TELA Bio to Announce First Quarter 2020 Financial Results and Host Conference Call on May 12, 2020

      MALVERN, Pa., April 28, 2020 -- TELA Bio, Inc. ("TELA Bio") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new.

    • GlobeNewswire

      TELA Bio Announces Changes to its Board of Directors

      MALVERN, Pa., April 23, 2020 -- TELA Bio, Inc. ("TELA Bio") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new.

    • TELA Bio, Inc. (NASDAQ:TELA) Just Reported And Analysts Have Been Cutting Their Estimates
      Simply Wall St.

      TELA Bio, Inc. (NASDAQ:TELA) Just Reported And Analysts Have Been Cutting Their Estimates

      TELA Bio, Inc. (NASDAQ:TELA) just released its latest yearly results and things are looking bullish. Results overall...

    • GlobeNewswire

      TELA Bio Announces Fourth Quarter and Full Year 2019 Financial Results

      MALVERN, Pa., March 27, 2020 -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new.

    • ACCESSWIRE

      TELA Bio Inc to Host Earnings Call

      NEW YORK, NY / ACCESSWIRE / March 27, 2020 / TELA Bio Inc (NASDAQ:TELA) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 27, 2020 at 8:00 AM Eastern ...

    • GlobeNewswire

      TELA Bio to Announce Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on March 27, 2020

      MALVERN, Pa., March 11, 2020 -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new.

    • GlobeNewswire

      TELA Bio Announces Publication of Results from In-Vivo Study Demonstrating Favorable Response to Reinforced Biologics in Hernia Repair

      TELA Bio, Inc. (“TELA”) (TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced data from a non-human primate study demonstrating favorable response to reinforced biologic material used in a hernia repair compared to seven clinically used biologic and synthetic products. The data are published online in the journal, Hernia, the world journal of hernia and abdominal wall surgery, in an article entitled “In-vivo evaluation of a reinforced ovine biologic: a comparative study to available hernia mesh repair materials.” Hernia is published in cooperation with the American Hernia Society, the European Hernia Society, the Americas Hernia Society, and the Asia Pacific Hernia Society.

    • GlobeNewswire

      TELA Bio Announces Appointment of New Chief Commercial Officer

      TELA Bio, Inc. (“TELA”) (TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announces the appointment of Peter Murphy to the newly created role of Chief Commercial Officer. In this position, Mr. Murphy will be responsible for the Company’s continued strategic expansion of its commercial operations. “Peter brings tremendous experience at top healthcare companies to build on our momentum as a commercial organization and bolster our efforts in creating a cohesive commercial organization dedicated to serving the needs of our patients, surgeons and hospital customers,” said Antony Koblish, co-founder, President and Chief Executive Officer of TELA Bio.

    • GlobeNewswire

      TELA Bio Announces Preliminary Revenue for Fourth Quarter and Full Year 2019

      TELA Bio, Inc. (“TELA”) (TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announces unaudited preliminary revenue for the fourth quarter and full year 2019. The company expects reported revenue for the fourth quarter of 2019 to be $4.7 million to $4.9 million, an increase of 94%-102% compared to $2.4 million in the fourth quarter of 2018. The company expects reported revenue for the full year of 2019 to be $15.3 million to $15.5 million, an increase of 85%-87% compared to $8.3 million for the full year of 2018.

    • GlobeNewswire

      TELA Bio Announces Third Quarter 2019 Financial Results

      Revenue increased 80% year-over-year to $4.0 million Completed initial public offering in November 2019, raising net proceeds of $50.7 million MALVERN, Pa., Dec. 18, 2019 --.

    • GlobeNewswire

      TELA Bio Awarded Contract with HealthTrust Purchasing Group

      MALVERN, Pa., Dec. 06, 2019 -- TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new.

    • GlobeNewswire

      TELA Bio Appoints Federica O’Brien to Board of Directors

      MALVERN, Pa., Nov. 13, 2019 -- TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new.

    • GlobeNewswire

      TELA Bio Announces Closing of Initial Public Offering of Common Stock

      MALVERN, Pa., Nov. 13, 2019 -- TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new.

    • GlobeNewswire

      TELA Bio Announces Pricing of Initial Public Offering of Common Stock

      TELA Bio, Inc. (“TELA”), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced the pricing of its initial public offering of 4,000,000 shares of common stock at a public offering price of $13.00 per share, before underwriting discounts and commissions, for gross proceeds of $52.0 million. All shares of common stock are being offered by TELA. TELA has granted the underwriters a 30-day option to purchase up to 600,000 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions.